45

45.3 years (SD 13.6); p=0.0035) and less likely to possess calcinosis (33.8% vs 58.0%, p=0.002) than scleroderma individuals without malignancy. (3/80, 3.8%; p=0.003). Individuals with anti-RPA194 and anti-RPC155 were significantly less likely to have severe gastrointestinal disease (26.3% vs 51.0%, p=0.043) than individuals with only anti-RPC155. Conclusions: Anti-RPA194 antibodies are enriched in anti-RPC155-positive scleroderma individuals without malignancy. Since somatic mutations in the gene encoding in scleroderma patient cancers appears to play a role in immune response initiation against D149 Dye RPC155 in Rabbit Polyclonal to TNF Receptor I those individuals, these data raise the probability the development of immune reactions to both RPC155 and RPA194 may influence clinical cancer emergence. Further study is required to define whether different autoantibody mixtures have energy as tools for malignancy risk stratification in scleroderma. Keywords: systemic sclerosis, malignancy, autoantibodies Introduction Growing data suggest that subsets of systemic sclerosis (scleroderma) individuals may have cancer-induced autoimmunity (1). This relationship between malignancy and scleroderma emergence has been most impressive among scleroderma individuals with antibodies against the large subunit of RNA polymerase III (RPC155). Scleroderma individuals with these autoantibodies have a significantly higher risk of malignancy within a short interval of scleroderma onset compared to scleroderma individuals without anti-RPC155 antibodies (2C7). Furthermore, recent data demonstrate that this translates to a 2.8-fold increased risk of cancer within 3 years of scleroderma onset when compared to the D149 Dye expected cancer incidence in the general population (8). Mechanistic studies have shown that genetic alterations (somatic mutations and/or loss of heterozygosity) are present in the gene (locus) that encodes for RPC155 in some of these individuals cancers, with development of both mutation-specific and cross-reactive immune responses (9). While these data strongly suggest a model of cancer-induced autoimmunity, it is notable that ~85% of scleroderma individuals with anti-RPC155 antibodies do not manifest a malignancy clinically over considerable follow-up (8). These data raise the tantalizing probability that malignancy may be an underlying result in for scleroderma in most individuals with anti-RPC155 antibodies, with the anti-tumor immune response becoming variably successful in removing the malignancy or keeping it in equilibrium such that it does not emerge (10). With this context, an important relevant property of the immune response is definitely its ability to diversify to additional epitopes within the primary target (intramolecular distributing) and also to additional proteins that bind to the primary target at some stage in its functional cycle (intermolecular distributing) (11). It is noteworthy that many targets of the autoimmune response in scleroderma (e.g. RNA polymerases, the small spliceosome and the centromere) are multi-component complexes. Furthermore, multiple components of these complexes are identified by autoantibodies, suggesting antigenic distributing (12). We hypothesized the immune response in anti-RPC155 positive scleroderma individuals in whom malignancy does not emerge might target additional autoantigens. To address this, we in the beginning studied a small group of individuals with anti-RPC155 antibodies with and without malignancy, and compared the autoantibody specificities in these 2 organizations by immunoprecipitation. Interestingly, in anti-RPC155 antibody positive individuals without malignancy, a 194 kDa protein was enriched. Noting the molecular excess weight, the prior description of RNA polymerase I as an autoantigen in scleroderma (13), and the observation that an inhibitor inducing damage of the catalytic subunit of RNA polymerase I (RPA194) is definitely itself an effective anti-cancer agent (14), we D149 Dye pursued whether, and then rapidly confirmed, the 194 kDa protein was RPA194. When the rate of recurrence of RPA194 antibodies was assayed in a large cohort of anti-RPC155-positive scleroderma individuals D149 Dye with and without malignancy, we confirmed that anti-RPA194 antibodies were enriched among anti-RPC155 individuals without malignancy. These data strongly suggest that scleroderma individuals focusing on the catalytic components of both RNA polymerase I and III complexes (that is, RPA194 and RPC155, respectively) are associated with decreased emergence of malignancy, raising the possibility that the combined immune reactions may impact tumor survival and fitness. These observations have important implications for understanding the mechanisms underlying the association of malignancy and scleroderma, as well as control of malignancy by the immune system. Knowing the RPA194 antibody status in anti-RPC155-positive individuals may also enable improved precision in malignancy prediction with this subgroup. Methods Study human population. Individuals with systemic sclerosis (scleroderma), as defined from the 2013 ACR/EULAR classification criteria, 1980 ACR criteria, or having at least 3 of 5 CREST (calcinosis, Raynauds trend, esophageal dysmotility, sclerodactyly and telangiectasia) criteria, and a banked serum sample were included for study (15, 16). One hundred sixty-eight scleroderma individuals with anti-RPC155 antibodies were identified for this study (RPC155 antibody status was determined by clinically acquired assays): 80 with a history of malignancy.